USD
$0.00
(0.00%
)At Close (As of Oct 16, 2025)
$817.45M
Market Cap
-
P/E Ratio
-0.98
EPS
$9.72
52 Week High
$2.21
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$31K |
Total Revenue | $0 |
Cost Of Revenue | $31K |
Costof Goods And Services Sold | $31K |
Operating Income | -$80M |
Selling General And Administrative | $18M |
Research And Development | $62M |
Operating Expenses | $80M |
Investment Income Net | - |
Net Interest Income | $5.5M |
Interest Income | $5.5M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $31K |
Income Before Tax | -$74M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$74M |
Comprehensive Income Net Of Tax | - |
Ebit | -$74M |
Ebitda | -$74M |
Net Income | -$74M |
Field | Value (USD) |
---|---|
Total Assets | $175M |
Total Current Assets | $171M |
Cash And Cash Equivalents At Carrying Value | $94M |
Cash And Short Term Investments | $94M |
Inventory | - |
Current Net Receivables | $700K |
Total Non Current Assets | $4.3M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | $0 |
Short Term Investments | $74M |
Other Current Assets | $2.6M |
Other Non Current Assets | - |
Total Liabilities | $13M |
Total Current Liabilities | $12M |
Current Accounts Payable | $5.8M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $632K |
Total Non Current Liabilities | $1.5M |
Capital Lease Obligations | $1.6M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $1.6M |
Other Current Liabilities | $5.5M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $162M |
Treasury Stock | - |
Retained Earnings | -$404M |
Common Stock | $87K |
Common Stock Shares Outstanding | $76M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$69M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $31K |
Capital Expenditures | $0 |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$15M |
Cashflow From Financing | $107M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$74M |
Field | Value (USD) |
---|---|
Gross Profit | -$31K |
Total Revenue | $0 |
Cost Of Revenue | $31K |
Costof Goods And Services Sold | $31K |
Operating Income | -$80M |
Selling General And Administrative | $18M |
Research And Development | $62M |
Operating Expenses | $80M |
Investment Income Net | - |
Net Interest Income | $5.5M |
Interest Income | $5.5M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $31K |
Income Before Tax | -$74M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$74M |
Comprehensive Income Net Of Tax | - |
Ebit | -$74M |
Ebitda | -$74M |
Net Income | -$74M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Rezolute, Inc. is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, dedicated to developing innovative therapies for rare and metabolic diseases. The company boasts a promising pipeline targeting significant unmet medical needs, underpinned by its commitment to scientific advancement and clinical excellence. Through strategic collaborations and a focus on improving patient outcomes, Rezolute is uniquely positioned to make a substantial impact in the biopharmaceutical sector, aiming to transform the treatment landscape for underserved patient populations.